JP2018511321A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511321A5 JP2018511321A5 JP2017550874A JP2017550874A JP2018511321A5 JP 2018511321 A5 JP2018511321 A5 JP 2018511321A5 JP 2017550874 A JP2017550874 A JP 2017550874A JP 2017550874 A JP2017550874 A JP 2017550874A JP 2018511321 A5 JP2018511321 A5 JP 2018511321A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- cell
- mhc
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140767P | 2015-03-31 | 2015-03-31 | |
| US62/140,767 | 2015-03-31 | ||
| GB1505585.8 | 2015-03-31 | ||
| GBGB1505585.8A GB201505585D0 (en) | 2015-03-31 | 2015-03-31 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| PCT/EP2016/056601 WO2016156230A1 (en) | 2015-03-31 | 2016-03-24 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020192310A Division JP7272667B2 (ja) | 2015-03-31 | 2020-11-19 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
| JP2020192308A Division JP2021048853A (ja) | 2015-03-31 | 2020-11-19 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
| JP2020192309A Division JP2021048854A (ja) | 2015-03-31 | 2020-11-19 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
| JP2020192307A Division JP2021048852A (ja) | 2015-03-31 | 2020-11-19 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511321A JP2018511321A (ja) | 2018-04-26 |
| JP2018511321A5 true JP2018511321A5 (enExample) | 2019-03-28 |
| JP7146399B2 JP7146399B2 (ja) | 2022-10-04 |
Family
ID=53178474
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550874A Expired - Fee Related JP7146399B2 (ja) | 2015-03-31 | 2016-03-24 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
| JP2023010823A Pending JP2023061974A (ja) | 2015-03-31 | 2023-01-27 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
| JP2023197848A Pending JP2024028730A (ja) | 2015-03-31 | 2023-11-22 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023010823A Pending JP2023061974A (ja) | 2015-03-31 | 2023-01-27 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
| JP2023197848A Pending JP2024028730A (ja) | 2015-03-31 | 2023-11-22 | 腎細胞がん（ｒｃｃ）およびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドとスキャフォールドの組み合わせ |
Country Status (25)
| Country | Link |
|---|---|
| US (17) | US9993536B2 (enExample) |
| EP (4) | EP3517126A1 (enExample) |
| JP (3) | JP7146399B2 (enExample) |
| KR (2) | KR102451645B1 (enExample) |
| CN (2) | CN113912702A (enExample) |
| AR (3) | AR104114A1 (enExample) |
| AU (5) | AU2016240341B2 (enExample) |
| BR (1) | BR112017019804A2 (enExample) |
| CA (1) | CA2980814A1 (enExample) |
| CL (5) | CL2017002448A1 (enExample) |
| CO (1) | CO2017009616A2 (enExample) |
| CR (3) | CR20220163A (enExample) |
| EA (1) | EA037050B1 (enExample) |
| GB (1) | GB201505585D0 (enExample) |
| HK (1) | HK1247085A1 (enExample) |
| IL (3) | IL289444B (enExample) |
| MA (5) | MA41844A (enExample) |
| MX (2) | MX2017012504A (enExample) |
| MY (2) | MY199184A (enExample) |
| PE (2) | PE20231650A1 (enExample) |
| PH (2) | PH12017501651B1 (enExample) |
| SG (2) | SG10202001834UA (enExample) |
| TW (5) | TWI745127B (enExample) |
| UA (1) | UA124519C2 (enExample) |
| WO (1) | WO2016156230A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6494233B2 (ja) | 2013-10-03 | 2019-04-03 | 日東電工株式会社 | 粘膜ワクチン組成物 |
| US10092642B2 (en) | 2013-10-03 | 2018-10-09 | Nitto Denko Corporation | Mucosal vaccine composition |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| HK1244791A1 (zh) | 2015-03-31 | 2018-08-17 | 拜欧蒂姆公司 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| GB201604490D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| AU2018212584B2 (en) * | 2017-01-27 | 2020-12-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| WO2019050478A1 (en) * | 2017-09-05 | 2019-03-14 | Agency For Science, Technology And Research | BIOMARKERS OF RENAL CELL CARCINOMA WITH CLEAR CELLS |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| KR20200119840A (ko) | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN111413498B (zh) * | 2020-04-08 | 2023-08-04 | 复旦大学附属中山医院 | 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用 |
| CN116333995A (zh) * | 2020-07-14 | 2023-06-27 | 广州泛恩生物科技有限公司 | 基于cxcr6阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CR20230295A (es) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023153763A1 (ko) * | 2022-02-08 | 2023-08-17 | 고려대학교 산학협력단 | C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도 |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN117126283B (zh) * | 2022-05-19 | 2025-05-27 | 深圳市新产业生物医学工程股份有限公司 | 抗pic的抗体、试剂盒及检测pic的方法 |
| CN115074445B (zh) * | 2022-08-09 | 2023-08-08 | 河北医科大学第二医院 | Eno3在肾癌诊断及治疗中的应用 |
| NL2034657B1 (en) * | 2023-04-21 | 2024-10-28 | Academisch Ziekenhuis Leiden | RCN1-derived TEIPP neoantigens and uses thereof |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| DE69738157T2 (de) * | 1996-10-01 | 2008-05-08 | Bio-Rad Laboratories, Inc., Hercules | Polymorphismus und neue gene in der region des menschlichen hemochromatosisgens |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6670328B1 (en) * | 1997-06-24 | 2003-12-30 | Institut Pasteur De Lille | Proteins and peptides derived from protein ESM-1 and their uses in the treatment and diagnosis of diseases linked to leukocyte migration |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP1294748B1 (en) | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| US20070037165A1 (en) * | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| FR2816410B1 (fr) * | 2000-11-09 | 2003-04-18 | Pasteur Institut | Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire |
| FR2816214B1 (fr) * | 2000-11-09 | 2005-10-21 | Pasteur Institut | Utilisation d'un compose antagoniste de la proteine esm-1 pour la fabrication d'un medicament pour la prevention et/ou le traitement d'un cancer |
| US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| AU2002324451A1 (en) | 2001-06-21 | 2003-01-08 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| EP1537140B1 (en) | 2001-11-07 | 2013-01-02 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| WO2004003172A2 (en) | 2002-07-01 | 2004-01-08 | Pharmacia Corporation | Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| US20060204960A1 (en) * | 2002-10-25 | 2006-09-14 | Oncotherapy Science, Inc. | Method for diagnosing diffuse-type gastric cancers |
| EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
| WO2004048599A2 (en) * | 2002-11-22 | 2004-06-10 | Incyte Corporation | Transporters and ion channels |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| DE10313819A1 (de) * | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| ES2605443T3 (es) * | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| WO2005084116A2 (en) | 2004-01-27 | 2005-09-15 | Compugen Usa, Inc. | Calcium channel variants |
| US7569662B2 (en) | 2004-01-27 | 2009-08-04 | Compugen Ltd | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
| US7667001B1 (en) | 2004-01-27 | 2010-02-23 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20070026424A1 (en) | 2005-04-15 | 2007-02-01 | Powell Charles A | Gene profiles correlating with histology and prognosis |
| DE602005020046D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| SI1760089T1 (sl) | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
| EP2006377A4 (en) * | 2006-03-28 | 2009-12-09 | Dainippon Sumitomo Pharma Co | NEW TUMORANT PEPTIDES |
| US20070264651A1 (en) | 2006-04-05 | 2007-11-15 | Corixa Corporation | Methods, compositions, and kits for the detection and monitoring of kidney cancer |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| NZ582823A (en) * | 2007-07-27 | 2012-04-27 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| HUE025636T2 (en) * | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| FR2933304A1 (fr) * | 2008-07-07 | 2010-01-08 | Adocia | Composition synergique osteogenique |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| KR101161789B1 (ko) | 2008-12-10 | 2012-07-03 | 한국생명공학연구원 | 간암에 대한 신규 바이오마커 및 그의 용도 |
| JP5649589B2 (ja) | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用 |
| KR20120059553A (ko) | 2009-08-14 | 2012-06-08 | 제넨테크, 인크. | Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커 |
| US20120315283A1 (en) * | 2010-02-02 | 2012-12-13 | Dana-Farber Cancer Institute, Inc. | Methods of promoting tissue growth and tissue regeneration |
| WO2011119484A1 (en) * | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| JP2011211970A (ja) | 2010-03-31 | 2011-10-27 | Toray Ind Inc | インターフェロンに対する感受性又は応答性を予測する方法、キット及びマーカー遺伝子 |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2632955A1 (en) | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| WO2012112434A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using retargeted endopeptidases |
| US20120302573A1 (en) | 2011-05-25 | 2012-11-29 | Paul Francis Jackson | Methods of inhibiting pro matrix metalloproteinase activation |
| TW201302800A (zh) | 2011-06-10 | 2013-01-16 | 腫瘤療法 科學股份有限公司 | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2013177533A1 (en) * | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| WO2014087626A1 (en) * | 2012-12-04 | 2014-06-12 | Oncotherapy Science, Inc. | Sema5b peptides and vaccines containing the same |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| CN107074910B (zh) * | 2014-08-17 | 2022-02-18 | 塞里维瑞疗法公司 | 高级大分子转导域序列、编码其的多核苷酸及其用途 |
| IL301919A (en) | 2015-03-27 | 2023-06-01 | Immatics Biotechnologies Gmbh | Innovative peptides and a combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
-
2015
- 2015-03-31 GB GBGB1505585.8A patent/GB201505585D0/en not_active Ceased
-
2016
- 2016-03-23 MA MA041844A patent/MA41844A/fr unknown
- 2016-03-24 CR CR20220163A patent/CR20220163A/es unknown
- 2016-03-24 MY MYPI2022003398A patent/MY199184A/en unknown
- 2016-03-24 MA MA046305A patent/MA46305A/fr unknown
- 2016-03-24 BR BR112017019804-5A patent/BR112017019804A2/pt not_active Application Discontinuation
- 2016-03-24 EP EP19160307.5A patent/EP3517126A1/en active Pending
- 2016-03-24 PE PE2022002819A patent/PE20231650A1/es unknown
- 2016-03-24 MY MYPI2017703153A patent/MY181449A/en unknown
- 2016-03-24 EP EP19160336.4A patent/EP3517128A1/en not_active Withdrawn
- 2016-03-24 MA MA046304A patent/MA46304A/fr unknown
- 2016-03-24 KR KR1020177027590A patent/KR102451645B1/ko not_active Expired - Fee Related
- 2016-03-24 PE PE2017001627A patent/PE20180505A1/es unknown
- 2016-03-24 SG SG10202001834UA patent/SG10202001834UA/en unknown
- 2016-03-24 HK HK18106394.9A patent/HK1247085A1/zh unknown
- 2016-03-24 SG SG11201707043WA patent/SG11201707043WA/en unknown
- 2016-03-24 EA EA201791950A patent/EA037050B1/ru unknown
- 2016-03-24 PH PH1/2017/501651A patent/PH12017501651B1/en unknown
- 2016-03-24 WO PCT/EP2016/056601 patent/WO2016156230A1/en not_active Ceased
- 2016-03-24 AU AU2016240341A patent/AU2016240341B2/en not_active Ceased
- 2016-03-24 IL IL289444A patent/IL289444B/en unknown
- 2016-03-24 CR CR20220164A patent/CR20220164A/es unknown
- 2016-03-24 EP EP19160322.4A patent/EP3517127A1/en active Pending
- 2016-03-24 CN CN202111198057.3A patent/CN113912702A/zh active Pending
- 2016-03-24 MA MA40794A patent/MA40794A1/fr unknown
- 2016-03-24 UA UAA201708037A patent/UA124519C2/uk unknown
- 2016-03-24 CA CA2980814A patent/CA2980814A1/en active Pending
- 2016-03-24 PH PH1/2022/553212A patent/PH12022553212A1/en unknown
- 2016-03-24 MA MA046303A patent/MA46303A/fr unknown
- 2016-03-24 JP JP2017550874A patent/JP7146399B2/ja not_active Expired - Fee Related
- 2016-03-24 EP EP16715808.8A patent/EP3277310A1/en not_active Withdrawn
- 2016-03-24 MX MX2017012504A patent/MX2017012504A/es unknown
- 2016-03-24 CR CR20170440A patent/CR20170440A/es unknown
- 2016-03-24 KR KR1020227015914A patent/KR20220070328A/ko not_active Ceased
- 2016-03-24 CN CN201680020165.2A patent/CN107438619B/zh not_active Expired - Fee Related
- 2016-03-28 TW TW109136262A patent/TWI745127B/zh not_active IP Right Cessation
- 2016-03-28 AR ARP160100819A patent/AR104114A1/es not_active Application Discontinuation
- 2016-03-28 TW TW111113655A patent/TW202231656A/zh unknown
- 2016-03-28 TW TW105109709A patent/TWI758243B/zh not_active IP Right Cessation
- 2016-03-28 US US15/082,876 patent/US9993536B2/en not_active Expired - Fee Related
- 2016-03-28 TW TW109136260A patent/TWI758912B/zh not_active IP Right Cessation
- 2016-03-28 US US15/082,920 patent/US9931388B2/en not_active Expired - Fee Related
- 2016-03-28 TW TW109136263A patent/TWI756874B/zh not_active IP Right Cessation
-
2017
- 2017-08-29 IL IL254204A patent/IL254204B/en unknown
- 2017-09-22 CO CONC2017/0009616A patent/CO2017009616A2/es unknown
- 2017-09-28 CL CL2017002448A patent/CL2017002448A1/es unknown
- 2017-09-28 MX MX2022000219A patent/MX2022000219A/es unknown
- 2017-10-31 US US15/799,495 patent/US10105428B2/en active Active
-
2018
- 2018-05-14 US US15/978,700 patent/US10213498B2/en active Active
- 2018-08-03 US US16/054,561 patent/US10357552B2/en active Active
- 2018-11-23 CL CL2018003348A patent/CL2018003348A1/es unknown
- 2018-12-07 US US16/212,783 patent/US10363296B2/en active Active
- 2018-12-07 US US16/212,787 patent/US10314899B2/en active Active
-
2019
- 2019-03-13 AU AU2019201713A patent/AU2019201713B2/en not_active Ceased
- 2019-03-13 AU AU2019201714A patent/AU2019201714B2/en not_active Ceased
- 2019-03-13 AU AU2019201708A patent/AU2019201708B2/en not_active Ceased
- 2019-03-28 US US16/367,790 patent/US10548958B2/en active Active
- 2019-05-17 US US16/415,686 patent/US10449240B2/en active Active
- 2019-05-17 US US16/415,753 patent/US10478481B2/en active Active
- 2019-09-17 CL CL2019002663A patent/CL2019002663A1/es unknown
- 2019-12-16 US US16/715,846 patent/US10835586B2/en not_active Expired - Fee Related
-
2020
- 2020-06-11 AU AU2020203850A patent/AU2020203850B2/en not_active Ceased
- 2020-10-16 US US17/072,528 patent/US20210030854A1/en not_active Abandoned
-
2021
- 2021-02-19 AR ARP210100439A patent/AR121383A2/es unknown
- 2021-02-19 AR ARP210100436A patent/AR121380A2/es not_active Application Discontinuation
- 2021-05-07 US US17/314,492 patent/US11938176B2/en active Active
- 2021-07-05 CL CL2021001776A patent/CL2021001776A1/es unknown
- 2021-08-08 IL IL285434A patent/IL285434B/en unknown
- 2021-08-13 US US17/402,068 patent/US12221626B2/en active Active
- 2021-10-29 US US17/514,599 patent/US12059458B2/en active Active
- 2021-11-04 US US17/519,192 patent/US12005105B2/en active Active
-
2023
- 2023-01-27 JP JP2023010823A patent/JP2023061974A/ja active Pending
- 2023-03-21 CL CL2023000812A patent/CL2023000812A1/es unknown
- 2023-11-22 JP JP2023197848A patent/JP2024028730A/ja active Pending
-
2024
- 2024-12-27 US US19/003,495 patent/US20250154459A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518937A5 (enExample) | ||
| JP2018519243A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2018510628A5 (enExample) | ||
| JP2018521641A5 (enExample) | ||
| JP2021168652A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2019502360A5 (enExample) | ||
| JP2018520653A5 (enExample) | ||
| JP2018518956A5 (enExample) | ||
| JP2018509135A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP7480064B2 (ja) | パンアレルモデルによる新生抗原の特定方法 | |
| JP7668742B2 (ja) | Ｍｈｃクラスｉｉモデルによる新生抗原の特定 | |
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2021514178A5 (enExample) | ||
| JP7763588B2 (ja) | Ｔ細胞療法用の新生抗原の特定法 | |
| JP2019511214A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2017525336A5 (enExample) | ||
| JP2025143480A (ja) | ホットスポットを利用した新生抗原の特定 | |
| KR101391561B1 (ko) | Ｈｌａ-ａ*3303 구속성 ｗｔ1 펩티드, 및 그것을 포함하는 의약 조성물 | |
| JP2024041841A5 (enExample) | ||
| JP2024099580A5 (enExample) |